Normand Blais

9.9k total citations · 1 hit paper
228 papers, 6.4k citations indexed

About

Normand Blais is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Atomic and Molecular Physics, and Optics. According to data from OpenAlex, Normand Blais has authored 228 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Pulmonary and Respiratory Medicine, 68 papers in Oncology and 63 papers in Atomic and Molecular Physics, and Optics. Recurrent topics in Normand Blais's work include Lung Cancer Treatments and Mutations (53 papers), Advanced Chemical Physics Studies (46 papers) and Lung Cancer Research Studies (27 papers). Normand Blais is often cited by papers focused on Lung Cancer Treatments and Mutations (53 papers), Advanced Chemical Physics Studies (46 papers) and Lung Cancer Research Studies (27 papers). Normand Blais collaborates with scholars based in Canada, United States and France. Normand Blais's co-authors include Donald G. Truhlar, Don L. Bunker, C. Alden Mead, Bruce C. Garrett, A. J. C. Varandas, Franklin B. Brown, E. A. Walters, Luis Corrales, Samer Tabchi and DG Gilliland and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Chemical Society and The Journal of Chemical Physics.

In The Last Decade

Normand Blais

217 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia

2021 128 citations Normand Blais et al. profile →

Peers

Countries citing papers authored by Normand Blais

Since Specialization

Citations

This map shows the geographic impact of Normand Blais's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Normand Blais with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Normand Blais more than expected).

Fields of papers citing papers by Normand Blais

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Normand Blais. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Normand Blais. The network helps show where Normand Blais may publish in the future.

Co-authorship network of co-authors of Normand Blais

This figure shows the co-authorship network connecting the top 25 collaborators of Normand Blais. A scholar is included among the top collaborators of Normand Blais based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Normand Blais. Normand Blais is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC 2025 ·Lung Cancer ·Barbara Melosky, Quincy S. Chu, Rosalyn A. Juergens, Stephanie Snow, Normand Blais, Parneet Cheema, Randeep Sangha, Jason Agulnik, (unknown), Ronald L. Burkes, (unknown), Mark Vincent, Geoffrey Liu	0
2	Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial 2025 ·Lung Cancer ·Anne‐Marie C. Dingemans, Konstantinos Syrigos, Lorenzo Livi, (unknown), Sang‐We Kim, Yuanbin Chen, Enriqueta Felip, Frank Griesinger, Kadoaki Ohashi, Gérard Zalcman, Brett Hughes, Jens Benn Sørensen, Normand Blais, Carlos Gil Ferreira, Colin R. Lindsay, Rafał Dziadziuszko, Patrick J. Ward, (unknown), Yang Wang, Solange Peters	0
3	Management of bleeding and invasive procedures in patients treated with anti–factor XI(a) anticoagulants: proposals from the French Working Group on Perioperative Haemostasis and French Society of Thrombosis and Haemostasis 2025 ·Research and Practice in Thrombosis and Haemostasis ·Anne Godiér, Dominique Lasne, Anne‐Céline Martin, Gilles Pernod, Pierre Albaladejo, Emmanuel de Maistre, Pierre Fontana, (unknown), Grégoire Le Gal, Jerrold H. Levy, Mikaël Mazighi, François Mullier, Philippe Nguyên, Stéphanie Roullet, Jean‐François Schved, Piérre Siè, Normand Blais, Isabelle Gouin‐Thibault, Sophie Susen	2
4	Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study) 2025 ·Current Oncology ·(unknown), (unknown), Raafat Alameddine, Marie Florescu, Mustapha Tehfé, Bertrand Routy, Arielle Elkrief, Wiam Belkaïd, Antoine Desîlets, Xiaoduan Weng, (unknown), Félix Blanc‐Durand, (unknown), Goulnar Kasymjanova, Jason Agulnik, Normand Blais	1
5	A phase II trial to evaluate the epithelial-to-mesenchymal (EMT) inhibitor sotevtamab combined with docetaxel in patients with metastatic non-small cell lung cancer following failure of primary chemoimmunotherapy. 2024 ·Journal of Clinical Oncology ·Normand Blais, (unknown), (unknown), Catherine Labbé, Louis Gaboury, Vincent Quoc‐Huy Trinh, Julia V. Burnier, (unknown), (unknown), Julie Laurin, Mario Filion, Jacques Jolivet, Lauren A. Byers	1
6	Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience 2023 ·Current Oncology ·(unknown), (unknown), Stephanie Snow, Paul Wheatley‐Price, Barbara Melosky, Rosalyn A. Juergens, Quincy S. Chu, Normand Blais, Shantanu Banerji, Ryan Ng, (unknown), (unknown), (unknown), Geoffrey Liu	4
7	Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC 2023 ·Current Oncology ·Parneet Cheema, Shantanu Banerji, Normand Blais, Quincy S. Chu, Rosalyn A. Juergens, Natasha B. Leighl, Adrian G. Sacher, Brandon S. Sheffield, Stephanie Snow, Mark Vincent, (unknown), Stephen Yip, Barbara Melosky	1
8	Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process 2023 ·Current Oncology ·James Tankel, Jonathan Spicer, Quincy S. Chu, Pierre Fiset, Biniam Kidane, Natasha B. Leighl, Philippe Joubert, Donna E. Maziak, David A. Palma, Anna McGuire, Barbara Melosky, Stephanie Snow, Houda Bahig, Normand Blais	4
9	Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases 2023 ·Neuro-Oncology Advances ·Philip Wong, Laura Masucci, Marie Florescu, (unknown), Valérie Panet-Raymond, Michel Pavic, Scott Owen, Laurence Masson‐Côté, Cynthia Ménard, Bertrand Routy, Mustapha Tehfé, (unknown), F Guilbert, Olivier Boucher, Sareh Keshavarzi, Normand Blais, David Roberge	11
10	Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations 2023 ·Lung Cancer ·A. Sun, Bassam Abdulkarim, Normand Blais, Jonathan Greenland, Alexander V. Louie, Barbara Melosky, Devin Schellenberg, Stephanie Snow, Geoffrey Liu	13
11	Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer 2023 ·Current Oncology ·Barbara Melosky, Natasha B. Leighl, David E. Dawe, Normand Blais, (unknown), Quincy S. Chu, Rosalyn A. Juergens, Peter Ellis, A. Sun, Devin Schellenberg, Diana N. Ionescu, Parneet Cheema	6
12	Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer 2022 ·Current Oncology ·Diana N. Ionescu, Tracy Stockley, Shantanu Banerji, Christian Couture, (unknown), Zhaolin Xu, Normand Blais, Parneet Cheema, Quincy S. Chu, Barbara Melosky, Natasha B. Leighl	20
13	Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus 2021 ·Current Oncology ·Marc Carrier, Normand Blais, Mark Crowther, Petr Kavan, Grégoire Le Gal, Otto Moodley, Sudeep Shivakumar, Deepa Suryanarayan, Vicky Tagalakis, Cynthia Wu, Agnes Lee	31
14	Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes 2019 ·Molecular Cancer Therapeutics ·(unknown), Maud Marques, Lise Tremblay, Nicole Bouchard, Razvan Diaconescu, Normand Blais, Christian Couture, Vincent Pelsser, Hangjun Wang, (unknown), Luisa Izzi, Karen Gambaro, Cyrla Hoffert, Archana Srivastava, Alan Spatz, Caroline Rousseau, (unknown), Victor Cohen, Gerald Batist, Jason Agulnik	20
15	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma 2019 ·Canadian Urological Association Journal ·Mark Warren, Michael Kolinsky, Christina M. Canil, Piotr Czaykowski, Srikala S. Sridhar, Peter C. Black, Christopher M. Booth, Wassim Kassouf, Libni Eapen, Som D. Mukherjee, Normand Blais, Bernhard J. Eigl, Eric Winquist, Naveen S. Basappa, Scott North	9
16	Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery 2018 ·The American Journal of Surgery ·Marc Carrier, Alon D. Altman, Normand Blais, (unknown), Deanna McLeod, (unknown), (unknown), Stephanie Young, Frank Schwenter	27
17	Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer 2016 ·Clinical Cancer Research ·Suresh S. Ramalingam, Normand Blais, Julien Mazières, Martin Reck, C. Michael Jones, Erzsébet Juhász, László Urbán, С. В. Орлов, Fabrice Barlési, Ebenezer A. Kio, (unknown), Qin Qin, Jiang Qian, Caroline Nickner, (unknown), Hao Xiong, Peter Ansell, Mark D. McKee, Vincent L. Giranda, В. А. Горбунова	65
18	Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) – September 2015 2016 ·Anaesthesia Critical Care & Pain Medicine ·Pierre Albaladejo, Fanny Bonhomme, Normand Blais, Jean‐Philippe Collet, David Faraoni, Pierre Fontana, Anne Godiér, Juan V. Llau, Dan Longrois, Emmanuel Marret, Patrick Mismetti, Nadia Rosencher, Stéphanie Roullet, Charles Marc Samama, Jean‐François Schved, Piérre Siè, A. Steib, Sophie Susen	53
19	Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors 2014 ·Current Oncology ·Vera Hirsh, Normand Blais, Ronald L. Burkes, Sunil Verma, Kenneth Croitoru	81
20	Prevention and Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer: A Consensus Statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea 2007 ·Current Oncology ·Jean A. Maroun, Lowell Anthony, Normand Blais, Ronald L. Burkes, Scot Dowden, George Dranitsaris, Benoît Samson, Amil M. Shah, Michael P. Thirlwell, Mark Vincent, (unknown)	109

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact